Skip to content

Survodutide

COMBINATION_PRODUCT14 trials

Sponsors

Boehringer Ingelheim

Conditions

Diabetes Mellitus, Type 2HealthyLiver FibrosisMetabolic Dysfunction Associated SteatohepatitisMetabolic Dysfunction Associated Steatohepatitis (MASH)Non-Alcoholic SteatoHepatitis (NASH)Non-alcoholic Steatohepatitis (NASH)Obesity

Phase 1

Phase 2

Phase 3

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
CompletedNCT06066528
Boehringer IngelheimDiabetes Mellitus, Type 2, Obesity
Start: 2023-11-27End: 2026-04-01Updated: 2026-08-06
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
CompletedNCT06066515
Boehringer IngelheimObesity
Start: 2023-11-25End: 2026-02-20Updated: 2026-03-12
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
CompletedNCT06077864
Boehringer IngelheimObesity
Start: 2023-11-20End: 2026-06-30Updated: 2026-09-17
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
CompletedNCT06176365
Boehringer IngelheimObesity
Start: 2024-01-16End: 2025-12-03Updated: 2026-04-30
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
CompletedNCT06214741
Boehringer IngelheimObesity, Overweight
Start: 2024-02-06End: 2026-01-28Updated: 2026-04-30
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
CompletedNCT06309992
Boehringer IngelheimNon-Alcoholic SteatoHepatitis (NASH), Obesity
Start: 2024-04-02End: 2025-12-02Updated: 2026-04-30
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
RecruitingNCT06632444
Boehringer IngelheimLiver Fibrosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Start: 2024-10-14End: 2031-12-27Target: 1800Updated: 2026-09-17
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
RecruitingNCT06632457
Boehringer IngelheimMetabolic Dysfunction Associated Steatohepatitis
Start: 2024-11-12End: 2029-06-05Target: 1590Updated: 2026-09-18
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
RecruitingNCT07754461
Boehringer IngelheimType 2 Diabetes
Start: 2026-08-24End: 2028-05-01Target: 600Updated: 2026-09-17

Related Papers

JACC Heart Failure2024-10-2322 citations
New England Journal of Medicine2024-06-07332 citations